Sugi Predict

Sugi Predict / Compounds / SCHEMBL21361501

SCHEMBL21361501

SCHEMBL21361501

C=C1CN(S(=O)(=O)c2ccc(N(C)C)cc2)CCCN(CC2CCCCC2)CCCN(S(=O)(=O)N2CCOCC2)C1

nearest known ligand 0.43

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ CD4 P01730 5/20 0.43
▸ SORT1 Q99523 1/20 0.42
▸ SMN1; SMN2 Q16637 2/20 0.41
▸ POLB P06746 1/20 0.40
▸ LMNA P02545 3/20 0.39
▸ KDM4E B2RXH2 2/20 0.39
▸ TSHR P16473 1/20 0.39
▸ HSD17B10 Q99714 1/20 0.39
▸ GAA P10253 3/20 0.39
▸ ALDH1A1 P00352 3/20 0.39
▸ KMT2A Q03164 3/20 0.36
▸ USP2 O75604 1/20 0.36
▸ MEN1 O00255 2/20 0.36
▸ HTT P42858 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21361623 0.94 CD4 (0.41) CD4SORT1SMN1; SMN2POLBLMNA
SCHEMBL21361494 0.94 CD4 (0.46) CD4SORT1SMN1; SMN2LMNAGAA
Hydrochloric Acid SCHEMBL21359286 0.93 CD4 (0.48) CD4SORT1SMN1; SMN2LMNAGAA
SCHEMBL21361524 0.91 CD4 (0.44) CD4SORT1SMN1; SMN2LMNAGAA
SCHEMBL21361532 0.91 CD4 (0.44) CD4SORT1SMN1; SMN2LMNAGAA
SCHEMBL21361451 0.88 CD4 (0.46) CD4SORT1LMNAALDH1A1KMT2A
SCHEMBL23102068 0.87 CD4 (0.41) CD4SORT1SMN1; SMN2LMNATSHR
SCHEMBL23102158 0.87 CD4 (0.56) CD4SORT1SMN1; SMN2POLBLMNA
SCHEMBL21361536 0.87 L3MBTL1 (0.42) CD4SORT1ALDH1A1KMT2AMEN1
SCHEMBL23102229 0.86 CD4 (0.53) CD4SORT1POLBALDH1A1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3765447-B1 TRIAZACYCLODODECANSULFONAMIDE (\"TCD\")-BASED PROTEIN SECRETION INHIBITORS KEZAR LIFE SCIENCES (US) 2023-07-12 — — EP disclosed
US-11578055-B2 Triazacyclododecansulfonamide (“TCD”)-based protein secretion inhibitors KEZAR LIFE SCIENCES (US) 2023-02-14 — — US disclosed
US-20220402891-A1 TRIAZACYCLODODECANSULFONAMIDE (TCD)-BASED PROTEIN SECRETION INHIBITORS ENODIA THERAPEUTICS SAS (FR) 2022-12-22 — — US disclosed
US-20210078974-A1 TRIAZACYCLODODECANSULFONAMIDE (\"TCD\")-BASED PROTEIN SECRETION INHIBITORS ENODIA THERAPEUTICS SAS (FR) 2021-03-18 — — US disclosed
WO-2019178510-A1 TRIAZACYCLODODECANSULFONAMIDE (\"TCD\")-BASED PROTEIN SECRETION INHIBITORS KEZAR LIFE SCIENCES (US) 2019-09-19 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11578055-B2 Triazacyclododecansulfonamide (“TCD”)-based protein secretion inhibitors SEC61B, SEC61A1, SEC61G CD4 3678/4885SORT1 2452/4885SMN1; SMN2 4582/4885
US-20220402891-A1 TRIAZACYCLODODECANSULFONAMIDE (TCD)-BASED PROTEIN SECRETION INHIBITORS SEC61B, SEC61A1, SEC61G CD4 3727/4885SORT1 2562/4885SMN1; SMN2 4499/4885
US-20210078974-A1 TRIAZACYCLODODECANSULFONAMIDE (\"TCD\")-BASED PROTEIN SECRETION INHIBITORS SEC61B, SEC61A1, SEC61G CD4 3471/4885SORT1 2267/4885SMN1; SMN2 4421/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.